CN109043129A - Enhance the prescription cream and preparation method thereof of pet heart function - Google Patents

Enhance the prescription cream and preparation method thereof of pet heart function Download PDF

Info

Publication number
CN109043129A
CN109043129A CN201810765038.6A CN201810765038A CN109043129A CN 109043129 A CN109043129 A CN 109043129A CN 201810765038 A CN201810765038 A CN 201810765038A CN 109043129 A CN109043129 A CN 109043129A
Authority
CN
China
Prior art keywords
oil
extract
heart function
vitamin
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810765038.6A
Other languages
Chinese (zh)
Inventor
王军军
褚广武
曹丽莉
李敏虹
冷军
巫良庭
李金磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHENZHEN HONGRUI BIOLOGICAL SCIENCE & TECHNOLOGY Co Ltd
Original Assignee
SHENZHEN HONGRUI BIOLOGICAL SCIENCE & TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHENZHEN HONGRUI BIOLOGICAL SCIENCE & TECHNOLOGY Co Ltd filed Critical SHENZHEN HONGRUI BIOLOGICAL SCIENCE & TECHNOLOGY Co Ltd
Priority to CN201810765038.6A priority Critical patent/CN109043129A/en
Publication of CN109043129A publication Critical patent/CN109043129A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/52—Juglandaceae (Walnut family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a kind of prescription cream for enhancing pet heart function, including following raw material components: Astragalus Root P.E, ginseng extract, Alisma extract, Rhizoma Polygonati Odorati extract, orange peel extract, l-carnitine tartrate, ubiquinone10, chicken meal, sepg whey albumen, synanthrin, xylo-oligosaccharide, oligofructose, grape seed oil, Semen Juglandis oil, linseed oil, sunflower oil, fish oil, taurine.The prescription cream of enhancing pet heart function of the invention has adjuvant treatment dog cat heart disease, enhances the effect of heart function.The invention also discloses the preparation methods of the prescription cream of enhancing pet heart function; it is uniform by the way that most of raw material first to be carried out to heating stirring, then taurine and vitamins are heated, it is deteriorated long very much so that ingredient is concentrated to be not easy heating afterwards; the preparation method is simple, convenient for operation.

Description

Enhance the prescription cream and preparation method thereof of pet heart function
Technical field
The present invention relates to pet technical field of nourishment, in particular to enhance the prescription cream and its system of pet heart function Preparation Method.
Background technique
With the development of pet industry, China pet gradually steps into aging, and in recent years, pet cardiovascular and cerebrovascular disease exists Pet clinic gradually increases, and pet heart disease is also the clinical veterinarian major issue to be faced, cardiopathic generation and nutrition Excessively, insufficient, old functional deterioration of activity etc. is related.Treating most of the drug of pet heart disease in the market is chemical classes Drug, and the prolonged application of chemical classes drug can generate certain side effect to pet, and be controlled using natural herbs auxiliary Pet heart disease is treated to have broad prospects, in addition, the favorite novel form product of pet is made in effective component, it is each to pet Class prevention and cure of heart disease have important application value.
Summary of the invention
One aspect of the present invention provides the prescription cream of enhancing pet heart function, including following raw material components: Radix Astragali Extract, ginseng extract, Alisma extract, Rhizoma Polygonati Odorati extract, orange peel extract, l-carnitine tartrate, ubiquinone10, chicken Powder, sepg whey albumen, synanthrin, xylo-oligosaccharide, oligofructose, grape seed oil, Semen Juglandis oil, linseed oil, sunflower oil, fish Oil, taurine.
Wherein, the prescription cream for enhancing pet heart function further includes vitamin.
Wherein, vitamin includes vitamin B1, vitamin B2, vitamin B6With one of vitamin E or a variety of.
Further, the prescription cream for enhancing pet heart function includes the raw material of following mass percentage content: Radix Astragali mentions Take object: 0.2%-2.5%, ginseng extract: 0.1%-1.2%, Alisma extract: 0.1%-1.2%, Rhizoma Polygonati Odorati extract: 0.05%-0.5%, orange peel extract: 0.05%-0.5%, l-carnitine tartrate: 1%-4%, ubiquinone10: 0.05%- 0.15%, chicken meal: 1%-7%, sepg whey albumen: 1%-7%, synanthrin: 3%-9%, xylo-oligosaccharide: 0.5%-4%, low Fructooligosaccharides: 1.5%-5%, grape seed oil: 0.5%-4%, Semen Juglandis oil: 0.2%-3%, linseed oil: 1%-4%, sunflower Seed oil: 0.5%-3%, fish oil: 1%-3%, taurine: 1%, vitamin B1: 0.01%, vitamin B2: 0.01%, vitamin B6: 0.006%, vitamin E: 0.3%；Surplus is supplied by water.
Further, Astragalus Root P.E: 1%, ginseng extract: 0.5%, Alisma extract: 0.5%, radix polygonati officinalis is extracted Object: 0.1%, orange peel extract: 0.15%, l-carnitine tartrate: 2.5%, ubiquinone10: 0.1%, chicken meal: 3%, separate Lactalbumin: 3%, synanthrin: 5%, xylo-oligosaccharide: 2%, oligofructose: 2.5%, grape seed oil: 2%, Semen Juglandis oil: 1.5%, linseed oil: 2.5%, sunflower oil: 1.5%, fish oil: 2%.
Wherein, each raw material has the beneficial effect that:
Astragalus Root P.E: the active constituent Astragaloside IV in Astragalus Root P.E can improve cardio-pulmonary function, reinforce heart contraction Power, protection cardiac muscle, heart failure resistance.
Ginseng extract: the active constituent ginsenoside energy anti-arrhythmia in ginseng extract；It resists myocardial ischemia, protect Cardiac muscle；Inhibit the effect of remodeling ventricle.
Alisma extract: rhizoma alismatis has effects that inducing diuresis for removing edema, excreting dampness, expels the heat-evil.Modern pharmacology research confirmation, rhizoma alismatis Plurality of active ingredients such as alisol A, B and rhizoma alismatis sesquiterpenoids etc. have lowering blood pressure and blood fat, antiatherosclerosis, the anti-heart The pharmacological actions such as myocardial ischemia.It is more to be clinically used for treatment hypertension, atherosclerosis, hyperlipidemia, coronary heart disease, myocardial ischemia etc. Kind cardiovascular disease, treatment effective mechanism may improve microcirculation with reduction peripheral resistance, inhibit platelet aggregation and resist dynamic Arteries and veins hardening etc. is related.
Rhizoma Polygonati Odorati extract: the total glycosides of active constituent radix polygonati officinalis in Rhizoma Polygonati Odorati extract advantageously reduces the oxygen demand of cardiac muscle, improves Cardiac function is advantageous to treatment heart failure.
Orange peel extract: the Nobiletin in orange peel can prevent heart disease；Nobiletin has anti-hemagglutination, anti-blood The effects of bolt forms, is antimycotic, anti-inflammatory, is carbohydrate metabolism promotor, can improve local microcirculation and nutrition supply, is sent out It waves it and prevents cardiopathic effect.
L-carnitine tartrate: strengthening myocardial function, assists to improve heart latter stage weak constitution.
Ubiquinone10: ubiquinone10Main function to cardiac muscle is to promote cellular oxidation phosphorylation, improves energy metabolism of myocardial, Mitigate damage of the ischemic to cardiac muscle；Increase the output quantity of cardiac blood；The effects of improving chronic congestion state and anti-arrhythmia cordis, from And cardiac muscle can be protected, improve heart function, provides enough energy for cardiac muscle.
Xylo-oligosaccharide: xylo-oligosaccharide has good physiological activity, adjustable intestines as a kind of soluble dietary fiber Road flora reduces blood pressure, physiology effect of blood lipid and blood glucose.It will be appreciated by those skilled in the art that xylo-oligosaccharide can also Have effects that identical oligosaccharide is substituted with other, for example, oligoisomaltose, galactooligosaccharide etc. should all fall into this hair Within bright protection scope.
Grape seed oil, Semen Juglandis oil, linseed oil, sunflower oil, fish oil: the omega3 fatty acid of offer can promote painstaking effort Pipe is sound, significantly lowers heart attack.It will be appreciated by those skilled in the art that removing above-mentioned grape seed oil, walnut kernel Oil, linseed oil, sunflower oil, outside fish oil, other vegetable oil and/or animal oil that omega3 fatty acid can be provided, such as odd Other equivalent substitutes such as sub- seed oil, sesame oil, olive oil and seal oil should also be fallen under the scope of the present invention.
Taurine: strengthening myocardial function, assists to improve heart latter stage weak constitution.Prevent the fast development of heart failure.
Vitamin B1: the most long-term pathological lesion that dog lacks includes nervous system and heart；Cat, which lacks, will appear electrocardiogram Variation, including sinus bradycardia.Clinically use vitamin B1Treatment can correct rapidly arrhythmia cordis.
Vitamin B2: dog acute deficiency will lead to anorexia, hypopnea, gradually weak, ataxia, chronic decrease appearance The symptoms such as anorexia, weight loss, visual impairment；Cat, which lacks, will appear the symptoms such as cataract, fatty liver.
Vitamin B6: dog cat, which lacks, will appear the pigmentosa anaemia of anorexia, weight loss, microcyte, including cardiac enlargement With the symptoms such as hypertrophy.
Vitamin E: the dog E that is deficient in vitamin will lead to anorexia, mental depression, expiratory dyspnea, finally go into a coma, ventricular muscles The symptoms such as meronecrosis.
Above-mentioned raw materials are cooperated by special ratios to be added in the prescription cream of enhancing pet heart function, has adjuvant treatment dog Cat heart disease enhances the effect of heart function.
Another aspect of the present invention provides the preparation method of the prescription cream of enhancing pet heart function, the method packet It includes:
(1) Astragalus Root P.E, ginseng extract, Alisma extract, Rhizoma Polygonati Odorati extract, orange peel extract, l-carnitine winestone Hydrochlorate, ubiquinone10, chicken meal, sepg whey albumen, synanthrin, xylo-oligosaccharide, oligofructose, grape seed oil, Semen Juglandis oil, flax Seed oil, sunflower oil, fish oil are weighed in investment material-compound tank by formula rate, and water homogenisation stirring is added by formula rate and is slurried；
(2) switching into vapour for material-compound tank is opened, when step (1) products therefrom is heated to 70-80 DEG C while stirring；
(3) it is sequentially added after boiling the stirring of step (2) products therefrom and weighs resulting vitamin and ox by formula rate Sulfonic acid continues to boil 20-30 minutes into material-compound tank.
Wherein, material-compound tank is steamed ingredients tank.
Wherein, the vapour pressure control of material-compound tank is 0.2-0.4MPa.
Wherein, the vapour pressure of the material-compound tank is preferably 0.3MPa.
It is uniform that most of raw material is first carried out heating stirring by above-mentioned preparation method, then by taurine and vitamins be added into Row heating is deteriorated very much long so that ingredient is concentrated to be not easy heating afterwards, and the preparation method is simple, convenient for operation.
Specific embodiment
Below with reference to embodiment, the present invention is described in further detail.
Embodiment 1:
Raw material total amount is 100 kilograms, wherein 0.2 kilogram of Astragalus Root P.E, 0.1 kilogram of ginseng extract, Alisma extract 0.1 kilogram, 0.05 kilogram of Rhizoma Polygonati Odorati extract, 0.05 kilogram of orange peel extract, 1 kilogram of l-carnitine tartrate, ubiquinone10 0.05 Kilogram, 1 kilogram of chicken meal, 7 kilograms of sepg whey albumen, 9 kilograms of synanthrin, 0.5 kilogram of xylo-oligosaccharide, 5 kilograms of oligofructose, Portugal Grape seed oily 0.5 kilogram, 0.2 kilogram of Semen Juglandis oil, 1 kilogram of linseed oil, 0.5 kilogram of sunflower oil, 1 kilogram of fish oil, taurine 1 Kilogram, vitamin B10.01 kilogram, vitamin B20.01 kilogram, vitamin B60.006 kilogram, 0.3 kilogram of vitamin E, water 71.424 kilograms.
Preparation method:
(1) Astragalus Root P.E, ginseng extract, Alisma extract, Rhizoma Polygonati Odorati extract, orange peel extract, l-carnitine winestone Hydrochlorate, ubiquinone10, chicken meal, sepg whey albumen, synanthrin, xylo-oligosaccharide, oligofructose, grape seed oil, Semen Juglandis oil, flax Seed oil, sunflower oil, fish oil are weighed in investment material-compound tank by formula rate, and water homogenisation stirring is added by formula rate and is slurried；
(2) switching into vapour for material-compound tank is opened, when step (1) products therefrom is heated to 70 DEG C while stirring；
(3) it is sequentially added after boiling the stirring of step (2) products therefrom and weighs resulting vitamin and ox by formula rate Sulfonic acid continues to boil 20 minutes into material-compound tank.
Wherein, material-compound tank is steamed ingredients tank, and the vapour pressure control of material-compound tank is 0.2MPa.
Embodiment 2:
Raw material total amount is 100 kilograms, wherein 1 kilogram of Astragalus Root P.E, 0.5 kilogram of ginseng extract, Alisma extract 0.5 kilogram, 0.1 kilogram of Rhizoma Polygonati Odorati extract, 0.15 kilogram of orange peel extract, 2.5 kilograms of l-carnitine tartrate, ubiquinone10 0.1 Kilogram, 3 kilograms of chicken meal, 3 kilograms of sepg whey albumen, 5 kilograms of synanthrin, 2 kilograms of xylo-oligosaccharide, 2.5 kilograms of oligofructose, Portugal Grape seed oily 2 kilograms, 1.5 kilograms of Semen Juglandis oil, 2.5 kilograms of linseed oil, 1.5 kilograms of sunflower oil, 2 kilograms of fish oil, taurine 1 Kilogram, vitamin B10.01 kilogram, vitamin B20.01 kilogram, vitamin B60.006 kilogram, 0.3 kilogram of vitamin E, water 68.824 kilograms.
Preparation method:
(1) Astragalus Root P.E, ginseng extract, Alisma extract, Rhizoma Polygonati Odorati extract, orange peel extract, l-carnitine winestone Hydrochlorate, ubiquinone10, chicken meal, sepg whey albumen, synanthrin, xylo-oligosaccharide, oligofructose, grape seed oil, Semen Juglandis oil, flax Seed oil, sunflower oil, fish oil are weighed in investment material-compound tank by formula rate, and water homogenisation stirring is added by formula rate and is slurried；
(2) switching into vapour for material-compound tank is opened, when step (1) products therefrom is heated to 75 DEG C while stirring；
(3) it is sequentially added after boiling the stirring of step (2) products therefrom and weighs resulting vitamin and ox by formula rate Sulfonic acid continues to boil 25 minutes into material-compound tank.
Wherein, material-compound tank is steamed ingredients tank, and the vapour pressure control of material-compound tank is 0.3MPa.
Embodiment 3:
Raw material total amount is 100 kilograms, wherein 2.5 kilograms of Astragalus Root P.E, 1.2 kilograms of ginseng extract, Alisma extract 1.2 kilograms, 0.5 kilogram of Rhizoma Polygonati Odorati extract, 0.5 kilogram of orange peel extract, 4 kilograms of l-carnitine tartrate, ubiquinone100.15 is public Jin, 7 kilograms of chicken meal, 1 kilogram of sepg whey albumen, 3 kilograms of synanthrin, 4 kilograms of xylo-oligosaccharide, 1.5 kilograms of oligofructose, grape 4 kilograms of seed oil, 3 kilograms of Semen Juglandis oil, 4 kilograms of linseed oil, 3 kilograms of sunflower oil, 3 kilograms of fish oil, 1 kilogram of taurine, dimension Raw element B10.01 kilogram, vitamin B20.01 kilogram, vitamin B60.006 kilogram, 0.3 kilogram of vitamin E, water 55.124 Kilogram.
Preparation method:
(1) Astragalus Root P.E, ginseng extract, Alisma extract, Rhizoma Polygonati Odorati extract, orange peel extract, l-carnitine winestone Hydrochlorate, ubiquinone10, chicken meal, sepg whey albumen, synanthrin, xylo-oligosaccharide, oligofructose, grape seed oil, Semen Juglandis oil, flax Seed oil, sunflower oil, fish oil are weighed in investment material-compound tank by formula rate, and water homogenisation stirring is added by formula rate and is slurried；
(2) switching into vapour for material-compound tank is opened, when step (1) products therefrom is heated to 80 DEG C while stirring；
(3) it is sequentially added after boiling the stirring of step (2) products therefrom and weighs resulting vitamin and ox by formula rate Sulfonic acid continues to boil 30 minutes into material-compound tank.
Wherein, material-compound tank is steamed ingredients tank, and the vapour pressure control of material-compound tank is 0.4MPa.
Enhance the clinical effectiveness test of the prescription cream of pet heart function
The prescription cream of enhancing pet heart function is adjuvant treatment dog cat heart disease, the nutrition of enhancing heart function effect Product.This experimental evidence autonomous Design evaluation index is chosen with the cardiopathic dog of different stage as experimental study object, is compared The clinical efficacy of the prescription cream of analysis enhancing pet heart function.
1 experimental animal: with the cardiopathic adult dogs of different stage 60, (excluding merging, there are the cardiopulmonary function of severe for selection The dog of energy obstacle, joint and nervous system disease etc. is only).
2 test samples: being made according to the prescription paste formulation of the enhancing pet heart function of embodiment 1,2,3, corresponding shape Prescription cream at the edible enhancing pet heart function of scheme one, scheme two and three or three kinds of scheme is spare.
3 groupings: will suffer from dog and be grouped at random, be provided with the prescription cream group that control group does not feed enhancing pet heart function 15；Test group is to press the prescription cream group 45 of recommended dose feeding enhancing pet heart function, is divided into application examples 1 group 15, Application examples 2 groups 15, application examples 3 groups 15, (the same batch dog grain of same producer's production) and drinking-water is freely eaten.Wherein, it answers The prescription cream of the edible enhancing pet heart function of 1 group of feeding scheme one of use-case, the edible enhancing of 2 groups of feeding schemes two of application examples The prescription cream of pet heart function, the prescription cream of the edible enhancing pet heart function of 3 groups of feeding schemes three of application examples.
4 Indexes of Evaluation Effect
4.1 classifications: the symptom for the dog performance having a heart disease has: the fatigue of unknown cause, palpitaition, shortness of breath, cough and asthma, four limbs Edema etc.；Judgement classification is carried out according to the case where animal quiescent condition and active performance.
4.2 therapeutic schemes: each group dog only all carries out conventional simple therapy (digitalis, diuretics etc.), answers on this basis Use-case group is continuously fed test sample 1 month, and control group is without feeding.
4.3 curative effect judging standard
4.3.1 curative effect situation is judged according to clinical symptoms.A is effective: clinical symptoms are substantially reduced, heart function improve 2 grades and More than.B is effective: clinical symptoms have substantially reduced, 1 grade of cardiac function improvement.C is invalid: without improvement or deteriorating.
4.3.2 curative effect situation is judged according to electrocardiogram map.
5 results
5.1 heart function clinical symptoms situations
Each comparison among groups after one month, the effective percentage that each application examples group heart function clinical symptoms improve are above control group, And 2 groups of effective percentage of application examples are higher than 1,3 two group of application examples, see Table 2 for details.Wherein, above-mentioned efficient equal to every group therapeutic effect is aobvious It imitates and effectively suffers from dog quantity and account for the percentage that the group suffers from dog total quantity.
The curative effect that 2 heart function clinical symptoms of table improve compares (example, %)
5.2 electrocardiogram situations
Each comparison among groups after one month are above control group according to the effective percentage of each application examples group of electrocardiogram paired observation, And 2 groups of effective percentage of application examples are higher than 1,3 two group of application examples, see Table 3 for details.
The curative effect that 3 electrocardiogram of table improves compares (example, %)
To sum up, the prescription cream for the enhancing pet heart function of being made by embodiment 1,2,3 all has certain improvement dog only Heart disease clinical symptoms and Electrocardiograph index enhance the effect of cardiac function；And embodiment 2 is optimum implementation.
Above-described is only some embodiments of the present invention.For those of ordinary skill in the art, not Under the premise of being detached from the invention design, various modifications and improvements can be made, these belong to protection model of the invention It encloses.

Claims (9)

1. enhancing the prescription cream of pet heart function, which is characterized in that including following raw material components: Astragalus Root P.E, ginseng mention Take object, Alisma extract, Rhizoma Polygonati Odorati extract, orange peel extract, l-carnitine tartrate, ubiquinone10, chicken meal, sepg whey egg White, synanthrin, xylo-oligosaccharide, oligofructose, grape seed oil, Semen Juglandis oil, linseed oil, sunflower oil, fish oil, taurine.
2. the prescription cream of enhancing pet heart function according to claim 1, it is characterised in that: further include vitamin.
3. the prescription cream of enhancing pet heart function according to claim 2, it is characterised in that: the vitamin includes dimension Raw element B1, vitamin B2, vitamin B6With one of vitamin E or a variety of.
4. the prescription cream of enhancing pet heart function according to claim 3, it is characterised in that: including following quality percentage Than the raw material of content: Astragalus Root P.E: 0.2%-2.5%, ginseng extract: 0.1%-1.2%, Alisma extract: 0.1%- 1.2%, Rhizoma Polygonati Odorati extract: 0.05%-0.5%, orange peel extract: 0.05%-0.5%, l-carnitine tartrate: 1%-4%, Ubiquinone10: 0.05%-0.15%, chicken meal: 1%-7%, sepg whey albumen: 1%-7%, synanthrin: 3%-9%, oligomeric wood Sugar: 0.5%-4%, oligofructose: 1.5%-5%, grape seed oil: 0.5%-4%, Semen Juglandis oil: 0.2%-3%, linseed Oil: 1%-4%, sunflower oil: 0.5%-3%, fish oil: 1%-3%, taurine: 1%, vitamin B1: 0.01%, vitamin B2: 0.01%, vitamin B6: 0.006%, vitamin E: 0.3%；Surplus is supplied by water.
5. the prescription cream of enhancing pet heart function according to claim 4, it is characterised in that: Astragalus Root P.E: 1%, Ginseng extract: 0.5%, Alisma extract: 0.5%, Rhizoma Polygonati Odorati extract: 0.1%, orange peel extract: 0.15%, l-carnitine wine Stone hydrochlorate: 2.5%, ubiquinone10: 0.1%, chicken meal: 3%, sepg whey albumen: 3%, synanthrin: 5%, xylo-oligosaccharide: 2%, Oligofructose: 2.5%, grape seed oil: 2%, Semen Juglandis oil: 1.5%, linseed oil: 2.5%, sunflower oil: 1.5%, fish Oil: 2%.
6. a kind of preparation method of the prescription cream of enhancing pet heart function as described in any one in claim 1-5, feature It is, which comprises
(1) Astragalus Root P.E, ginseng extract, Alisma extract, Rhizoma Polygonati Odorati extract, orange peel extract, l-carnitine tartrate, Ubiquinone10, chicken meal, sepg whey albumen, synanthrin, xylo-oligosaccharide, oligofructose, grape seed oil, Semen Juglandis oil, linseed oil, Sunflower oil, fish oil are weighed in investment material-compound tank by formula rate, and water homogenisation stirring is added by formula rate and is slurried；
(2) switching into vapour for material-compound tank is opened, when step (1) products therefrom is heated to 70-80 DEG C while stirring；
(3) it is sequentially added after boiling the stirring of step (2) products therefrom and weighs resulting vitamin and taurine by formula rate Into material-compound tank, continue to boil 20-30 minutes.
7. the preparation method of the prescription cream of enhancing pet heart function according to claim 6, it is characterised in that: described to match Batch can is steamed ingredients tank.
8. the preparation method of the prescription cream of enhancing pet heart function according to claim 7, it is characterised in that: described to match The vapour pressure control of batch can is 0.2-0.4MPa,
9. the preparation method of the prescription cream of enhancing pet heart function according to claim 8, it is characterised in that: described to match The vapour pressure of batch can is preferably 0.3MPa.
CN201810765038.6A 2018-07-12 2018-07-12 Enhance the prescription cream and preparation method thereof of pet heart function Pending CN109043129A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810765038.6A CN109043129A (en) 2018-07-12 2018-07-12 Enhance the prescription cream and preparation method thereof of pet heart function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810765038.6A CN109043129A (en) 2018-07-12 2018-07-12 Enhance the prescription cream and preparation method thereof of pet heart function

Publications (1)

Publication Number Publication Date
CN109043129A true CN109043129A (en) 2018-12-21

Family

ID=64816180

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810765038.6A Pending CN109043129A (en) 2018-07-12 2018-07-12 Enhance the prescription cream and preparation method thereof of pet heart function

Country Status (1)

Country Link
CN (1) CN109043129A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112890018A (en) * 2021-03-01 2021-06-04 中农宠物营养研究院(江苏)有限公司 Nutritional paste beneficial to pet blood replenishing and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104137952A (en) * 2014-08-08 2014-11-12 上海比瑞吉宠物用品有限公司 Nutrient food for maintaining heart health of dogs and cats and preparation method of nutrient food
CN104784443A (en) * 2015-05-04 2015-07-22 威海御膳坊生物科技有限公司 Coenzyme Q10 compound preparation
CN107184598A (en) * 2017-04-28 2017-09-22 深圳市众康动保科技有限公司 A kind of pet heart disease composite tablet
CN107691854A (en) * 2017-10-17 2018-02-16 深圳市红瑞生物科技有限公司 Pet eye illness cream and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104137952A (en) * 2014-08-08 2014-11-12 上海比瑞吉宠物用品有限公司 Nutrient food for maintaining heart health of dogs and cats and preparation method of nutrient food
CN104784443A (en) * 2015-05-04 2015-07-22 威海御膳坊生物科技有限公司 Coenzyme Q10 compound preparation
CN107184598A (en) * 2017-04-28 2017-09-22 深圳市众康动保科技有限公司 A kind of pet heart disease composite tablet
CN107691854A (en) * 2017-10-17 2018-02-16 深圳市红瑞生物科技有限公司 Pet eye illness cream and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
贾波: "《方剂学》", 31 August 2016 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112890018A (en) * 2021-03-01 2021-06-04 中农宠物营养研究院(江苏)有限公司 Nutritional paste beneficial to pet blood replenishing and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102406860B (en) Composition for preventing and treating diabetes, and preparation method and use thereof
CN106234926B (en) Selenium-rich five cereals nutrient instant powder and preparation method thereof
CN103005281B (en) High-nutrient healthcare rice and preparation method thereof
CN102687822B (en) Wolfberry chewable tablet and manufacturing method thereof
CN108477609A (en) A kind of burdock weight losing meal-replacing stick and preparation method thereof
CN108837036A (en) A kind of blood fat-reducing blood pressure-decreasing, the preparation for preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof
CN108576394A (en) Aged companion pet health nutrient cream
CN103652636A (en) Hearth care three-wheat rice crust
CN102499291B (en) Milk powder with functions of maintaining beauty and keeping young and improving immunity of organism and preparation method thereof
CN106550970A (en) A kind of Tartary buckwheat cake
CN104383259A (en) Bitter gourd and mulberry leaf chromium-rich capsule and preparation method thereof
CN109170305A (en) Improve the prescription cream and preparation method thereof of pet liver function
CN109043129A (en) Enhance the prescription cream and preparation method thereof of pet heart function
CN103478560B (en) Nutrition rice prepared through milk and gynostemma pentaphylla
CN104397542A (en) Millet-radix polygoni multiflori porridge
CN102090637A (en) Collagen-containing compound nutritious powder
CN108066384A (en) A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof
CN106260521A (en) Additive for farm animal feed and application thereof
US20040071799A1 (en) Herbal compositions and methods for effecting weight loss in humans
CN107692122A (en) A kind of sweet-scented cake of strengthen immunity and preparation method thereof
CN106798854A (en) Emblic mulberry leaf piece and preparation method thereof
CN106962667A (en) A kind of feed addictive for improving chicken egg productivity and preparation method thereof
CN106721259A (en) A kind of feed and its method for breeding for increasing sow production efficiency
CN1183936C (en) Medicine for treating hypertension and method for preparing medicinal tea thereof
KR102483929B1 (en) Composition of Supplementary Feed for Herbivores

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181221